Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  Fucikova, Jitka ^a,b   Moserova, Irena ^a,b   Urbanova, Linda ^a,b   Bezu, Lucillia ^c,d,e,f,g   Kepp, Oliver ^c,d,e,f,g   Cremer, Isabelle ^c,e,f   Salek, Cyril ^h   Strnad, Pavel ^b   Kroemer, Guido ^c,d,e,f,g,i   Galluzzi, Lorenzo ^c,d,e,f,g   Spisek, Radek ^a,b  

^a Sotio   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

ATP; Autophagy; Calreticulin; ER stress response; HSPs; Type I interferon

Indexed keywords

5' NUCLEOTIDASE; BECLIN 1; CALRETICULIN; CASPASE 7; CD39 ANTIGEN; CD47 ANTIGEN; CD94 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; F ACTIN; FORMYLPEPTIDE RECEPTOR LIKE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 1; MITOCHONDRIAL DNA; MYELOID DIFFERENTIATION FACTOR 88; PURINERGIC P2Y RECEPTOR; SCRAMBLASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; X BOX BINDING PROTEIN 1;

ADJUVANT CHEMORADIOTHERAPY; ANTIGEN PRESENTING CELL; AUTOPHAGY; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL DEATH; CELLULAR IMMUNITY; CELLULAR STRESS RESPONSE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CARCINOMA; DAMAGE ASSOCIATED MOLECULAR PATTERN; ENDOPLASMIC RETICULUM STRESS; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MOUTH SQUAMOUS CELL CARCINOMA; NEOPLASM; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT;

EID: 84938506465     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00402     Document Type: Review

References (225)

1. Ahrens, S., Zelenay, S., Sancho, D., Hanc, P., Kjaer, S., Feest, C., Fletcher, G., Durkin, C., Postigo, A., Skehel, M., Batista, F., Thompson, B., Way, M., Reis E Sousa, C., and Schulz, O. (2012). Factin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 36, 635-645. doi: 10.1016/j.immuni.2012.03.008.
2. Aliagas, E., Vidal, A., Texido, L., Ponce, J., Condom, E., and Martin-Satue, M. (2014). High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediators Inflamm 2014, 509027. doi: 10.1155/2014/509027.
3. Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J.P., Delaloge, S., Andre, F., Tursz, T., Kroemer, G., and Zitvogel, L. (2007a). The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220, 47-59. doi: 10.1111/j.1600-065X.2007.00573.x.
4. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F.J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J.P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., Andre, F., Delaloge, S., Tursz, T., Kroemer, G., and Zitvogel, L. (2007b). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13, 1050-1059. doi: 10.1038/nm1622.
5. Aquea, G., Bresky, G., Lancellotti, D., Madariaga, J.A., Zaffiri, V., Urzua, U., Haberle, S., and Bernal, G. (2014). Increased expression of P2RY2, CD248 and EphB1 in gastric cancers from Chilean patients. Asian Pac J Cancer Prev 15, 1931-1936.
6. Aranda, F., Vacchelli, E., Eggermont, A., Galon, J., Sautes-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2013). Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2, e26621. doi: 10.4161/onci.26621.
7. Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A., Galon, J., Sautes-Fridman, C., Cremer, I., Henrik Ter Meulen, J., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2014). Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 3, e29179. doi: 10.4161/onci.29179.
8. Arnold, T., Michlmayr, A., Baumann, S., Burghuber, C., Pluschnig, U., Bartsch, R., Steger, G., Gnant, M., Bergmann, M., Bachleitner-Hofmann, T., and Oehler, R. (2013). Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest 43, 286-291. doi: 10.1111/eci.12043.
9. Aymeric, L., Apetoh, L., Ghiringhelli, F., Tesniere, A., Martins, I., Kroemer, G., Smyth, M.J., and Zitvogel, L. (2010). Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 70, 855-858. doi: 10.1158/0008-5472.CAN-09-3566.
10. Bacher, N., Raker, V., Hofmann, C., Graulich, E., Schwenk, M., Baumgrass, R., Bopp, T., Zechner, U., Merten, L., Becker, C., and Steinbrink, K. (2013). Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res 73, 5647-5656. doi: 10.1158/0008-5472.CAN-12-3788.
11. Bao, G., Qiao, Q., Zhao, H., and He, X. (2010). Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol 8, 52. doi: 10.1186/1477-7819-8-52.
12. Bastid, J., Regairaz, A., Bonnefoy, N., Dejou, C., Giustiniani, J., Laheurte, C., Cochaud, S., Laprevotte, E., Funck-Brentano, E., Hemon, P., Gros, L., Bec, N., Larroque, C., Alberici, G., Bensussan, A., and Eliaou, J.F. (2015). Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 3, 254-265. doi: 10.1158/2326-6066.CIR-14-0018.
13. Basu, S., Binder, R.J., Suto, R., Anderson, K.M., and Srivastava, P.K. (2000). Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12, 1539-1546.
14. Beavis, P.A., Stagg, J., Darcy, P.K., and Smyth, M.J. (2012). CD73: a potent suppressor of antitumor immune responses. Trends Immunol 33, 231-237. doi: 10.1016/j.it.2012.02.009.
15. Becht, E., Goc, J., Germain, C., Giraldo, N.A., Dieu-Nosjean, M.C., Sautes-Fridman, C., and Fridman, W.H. (2014). Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother 63, 991-997. doi: 10.1007/s00262-014-1590-3.
16. Belli, F., Testori, A., Rivoltini, L., Maio, M., Andreola, G., Sertoli, M.R., Gallino, G., Piris, A., Cattelan, A., Lazzari, I., Carrabba, M., Scita, G., Santantonio, C., Pilla, L., Tragni, G., Lombardo, C., Arienti, F., Marchiano, A., Queirolo, P., Bertolini, F., Cova, A., Lamaj, E., Ascani, L., Camerini, R., Corsi, M., Cascinelli, N., Lewis, J.J., Srivastava, P., and Parmiani, G. (2002). Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20, 4169-4180.
17. Bergmann, C., Bachmann, H.S., Bankfalvi, A., Lotfi, R., Putter, C., Wild, C.A., Schuler, P.J., Greve, J., Hoffmann, T.K., Lang, S., Scherag, A., and Lehnerdt, G.F. (2011). Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 9, 139. doi: 10.1186/1479-5876-9-139.
18. Bezu, L., Gomes-De-Silva, L.C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., and Kroemer, G. (2015). Combinatorial strategies for the induction of immunogenic cell death. Front Immunol 6, 187. doi: 10.3389/fimmu.2015.00187.
19. Binder, R.J., Blachere, N.E., and Srivastava, P.K. (2001). Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem 276, 17163-17171. doi: 10.1074/jbc.M011547200.
20. Bloch, O., Crane, C.A., Fuks, Y., Kaur, R., Aghi, M.K., Berger, M.S., Butowski, N.A., Chang, S.M., Clarke, J.L., Mcdermott, M.W., Prados, M.D., Sloan, A.E., Bruce, J.N., and Parsa, A.T. (2014). Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 16, 274-279. doi: 10.1093/neuonc/not203.
21. Brenner, C., Galluzzi, L., Kepp, O., and Kroemer, G. (2013). Decoding cell death signals in liver inflammation. J Hepatol 59, 583-594. doi: 10.1016/j.jhep.2013.03.033.
22. Cao, H., Ye, H., Sun, Z., Shen, X., Song, Z., Wu, X., He, W., Dai, C., and Yang, J. (2014). Circulatory mitochondrial DNA is a pro-inflammatory agent in maintenance hemodialysis patients. PLoS One 9, e113179. doi: 10.1371/journal.pone.0113179.
23. Carp, H. (1982). Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med 155, 264-275.
24. Castro, F.A., Forsti, A., Buch, S., Kalthoff, H., Krauss, C., Bauer, M., Egberts, J., Schniewind, B., Broering, D.C., Schreiber, S., Schmitt, M., Hampe, J., Hemminki, K., and Schafmayer, C. (2011). TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 47, 1203-1210. doi: 10.1016/j.ejca.2010.12.011.
25. Chao, M.P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A.A., Gentles, A.J., Volkmer, J., Weiskopf, K., Willingham, S.B., Raveh, T., Park, C.Y., Majeti, R., and Weissman, I.L. (2010). Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2, 63ra94. doi: 10.1126/scitranslmed.3001375.
26. Chen, C.N., Chang, C.C., Su, T.E., Hsu, W.M., Jeng, Y.M., Ho, M.C., Hsieh, F.J., Lee, P.H., Kuo, M.L., Lee, H., and Chang, K.J. (2009). Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol 16, 524-533. doi: 10.1245/s10434-008-0243-1.
27. Chen, J.S., Hsu, Y.M., Chen, C.C., Chen, L.L., Lee, C.C., and Huang, T.S. (2010). Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NFkappaB-mediated integrin alphaV expression. J Biol Chem 285, 25458-25466. doi: 10.1074/jbc.M110.139345.
28. Chen, W.S., Chen, C.C., Chen, L.L., Lee, C.C., and Huang, T.S. (2013). Secreted heat shock protein 90alpha (HSP90alpha) induces nuclear factor-kappaB-mediated TCF12 protein expression to down-regulate E-cadherin and to enhance colorectal cancer cell migration and invasion. J Biol Chem 288, 9001-9010. doi: 10.1074/jbc.M112.437897.
29. Chen, X., Iliopoulos, D., Zhang, Q., Tang, Q., Greenblatt, M.B., Hatziapostolou, M., Lim, E., Tam, W.L., Ni, M., Chen, Y., Mai, J., Shen, H., Hu, D.Z., Adoro, S., Hu, B., Song, M., Tan, C., Landis, M.D., Ferrari, M., Shin, S.J., Brown, M., Chang, J.C., Liu, X.S., and Glimcher, L.H. (2014). XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 508, 103-107. doi: 10.1038/nature13119.
30. Chen, Y.C., Giovannucci, E., Lazarus, R., Kraft, P., Ketkar, S., and Hunter, D.J. (2005). Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 65, 11771-11778. doi: 10.1158/0008-5472.CAN-05-2078.
31. Chew, V., Tow, C., Huang, C., Bard-Chapeau, E., Copeland, N.G., Jenkins, N.A., Weber, A., Lim, K.H., Toh, H.C., Heikenwalder, M., Ng, I.O., Nardin, A., and Abastado, J.P. (2012). Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst 104, 1796-1807. doi: 10.1093/jnci/djs436.
32. Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J.V., Colgan, J.D., Hirashima, M., Uede, T., Takaoka, A., Yagita, H., and Jinushi, M. (2012). Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 13, 832-842. doi: 10.1038/ni.2376.
33. Chung, H.W., Lim, J.B., Jang, S., Lee, K.J., Park, K.H., and Song, S.Y. (2012). Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci 103, 1714-1721. doi: 10.1111/j.1349-7006.2012.02358.x.
34. Crane, C.A., Han, S.J., Ahn, B., Oehlke, J., Kivett, V., Fedoroff, A., Butowski, N., Chang, S.M., Clarke, J., Berger, M.S., Mcdermott, M.W., Prados, M.D., and Parsa, A.T. (2013). Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res 19, 205-214. doi: 10.1158/1078-0432.CCR-11-3358.
35. Crouse, J., Bedenikovic, G., Wiesel, M., Ibberson, M., Xenarios, I., Von Laer, D., Kalinke, U., Vivier, E., Jonjic, S., and Oxenius, A. (2014). Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity 40, 961-973. doi: 10.1016/j.immuni.2014.05.003.
36. Crouser, E.D., Shao, G., Julian, M.W., Macre, J.E., Shadel, G.S., Tridandapani, S., Huang, Q., and Wewers, M.D. (2009). Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors. Crit Care Med 37, 2000-2009. doi: 10.1097/CCM.0b013e3181a001ae.
37. Dai, J., Hu, Z., Dong, J., Xu, L., Pan, S., Jiang, Y., Jin, G., Chen, Y., and Shen, H. (2012). Host immune gene polymorphisms were associated with the prognosis of non-small-cell lung cancer in Chinese. Int J Cancer 130, 671-676. doi: 10.1002/ijc.26067.
38. Dardano, A., Falzoni, S., Caraccio, N., Polini, A., Tognini, S., Solini, A., Berti, P., Di Virgilio, F., and Monzani, F. (2009). 1513A>C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J Clin Endocrinol Metab 94, 695-698. doi: 10.1210/jc.2008-1322.
39. Davies, M.P., Barraclough, D.L., Stewart, C., Joyce, K.A., Eccles, R.M., Barraclough, R., Rudland, P.S., and Sibson, D.R. (2008). Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer 123, 85-88. doi: 10.1002/ijc.23479.
40. Dieude, M., Striegl, H., Tyznik, A.J., Wang, J., Behar, S.M., Piccirillo, C.A., Levine, J.S., Zajonc, D.M., and Rauch, J. (2011). Cardiolipin binds to CD1d and stimulates CD1d-restricted gammadelta T cells in the normal murine repertoire. J Immunol 186, 4771-4781. doi: 10.4049/jimmunol.1000921.
41. Doody, A.D., Kovalchin, J.T., Mihalyo, M.A., Hagymasi, A.T., Drake, C.G., and Adler, A.J. (2004). Glycoprotein 96 can chaperone both MHC class I-and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol 172, 6087-6092.
42. Drobits, B., Holcmann, M., Amberg, N., Swiecki, M., Grundtner, R., Hammer, M., Colonna, M., and Sibilia, M. (2012). Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 122, 575-585. doi: 10.1172/JCI61034.
43. Dudek, A.M., Garg, A.D., Krysko, D.V., De Ruysscher, D., and Agostinis, P. (2013). Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 24, 319-333. doi: 10.1016/j.cytogfr.2013.01.005.
44. Dumitriu, I.E., Bianchi, M.E., Bacci, M., Manfredi, A.A., and Rovere-Querini, P. (2007). The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81, 84-91. doi: 10.1189/jlb.0306171.
45. Duo, C.C., Gong, F.Y., He, X.Y., Li, Y.M., Wang, J., Zhang, J.P., and Gao, X.M. (2014). Soluble calreticulin induces tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6 production by macrophages through mitogen-activated protein kinase (MAPK) and NFkappaB signaling pathways. Int J Mol Sci 15, 2916-2928. doi: 10.3390/ijms15022916.
46. Elliott, M.R., Chekeni, F.B., Trampont, P.C., Lazarowski, E.R., Kadl, A., Walk, S.F., Park, D., Woodson, R.I., Ostankovich, M., Sharma, P., Lysiak, J.J., Harden, T.K., Leitinger, N., and Ravichandran, K.S. (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282-286. doi: 10.1038/nature08296.
47. Eric, A., Juranic, Z., Milovanovic, Z., Markovic, I., Inic, M., Stanojevic-Bakic, N., and Vojinovic-Golubovic, V. (2009). Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathol Oncol Res 15, 89-90. doi: 10.1007/s12253-008-9112-2.
48. Eton, O., Ross, M.I., East, M.J., Mansfield, P.F., Papadopoulos, N., Ellerhorst, J.A., Bedikian, A.Y., and Lee, J.E. (2010). Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med 8, 9. doi: 10.1186/1479-5876-8-9.
49. Fahmueller, Y.N., Nagel, D., Hoffmann, R.T., Tatsch, K., Jakobs, T., Stieber, P., and Holdenrieder, S. (2013). Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 132, 2349-2358. doi: 10.1002/ijc.27894.
50. Ferrer-Ferrer, M., Malespin-Bendana, W., Ramirez, V., Gonzalez, M.I., Carvajal, A., and Une, C. (2013). Polymorphisms in genes coding for HSP-70 are associated with gastric cancer and duodenal ulcer in a population at high risk of gastric cancer in Costa Rica. Arch Med Res 44, 467-474. doi: 10.1016/j.arcmed.2013.08.008.
51. Fridman, W.H., Pages, F., Sautes-Fridman, C., and Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12, 298-306. doi: 10.1038/nrc3245.
52. Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., and Spisek, R. (2011). Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 71, 4821-4833. doi: 10.1158/0008-5472.CAN-11-0950.
53. Fucikova, J., Moserova, I., Truxova, I., Hermanova, I., Vancurova, I., Partlova, S., Fialova, A., Sojka, L., Cartron, P.F., Houska, M., Rob, L., Bartunkova, J., and Spisek, R. (2014). High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 135, 1165-1177. doi: 10.1002/ijc.28766.
54. Fujita, M., Scheurer, M.E., Decker, S.A., Mcdonald, H.A., Kohanbash, G., Kastenhuber, E.R., Kato, H., Bondy, M.L., Ohlfest, J.R., and Okada, H. (2010). Role of type 1 IFNs in antiglioma immunosurveillance-using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 16, 3409-3419. doi: 10.1158/1078-0432.CCR-10-0644.
55. Galluzzi, L., Bravo-San Pedro, J.M., and Kroemer, G. (2014a). Organelle-specific initiation of cell death. Nat Cell Biol 16, 728-736. doi: 10.1038/ncb3005.
56. Galluzzi, L., Bravo-San Pedro, J.M., Vitale, I., Aaronson, S.A., Abrams, J.M., Adam, D., Alnemri, E.S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., Baehrecke, E.H., Bazan, N.G., Bertrand, M.J., Bianchi, K., Blagosklonny, M.V., Blomgren, K., Borner, C., Bredesen, D.E., Brenner, C., Campanella, M., Candi, E., Cecconi, F., Chan, F.K., Chandel, N.S., Cheng, E.H., Chipuk, J.E., Cidlowski, J.A., Ciechanover, A., Dawson, T.M., Dawson, V.L., De Laurenzi, V., De Maria, R., Debatin, K.M., Di Daniele, N., Dixit, V.M., Dynlacht, B.D., El-Deiry, W.S., Fimia, G.M., Flavell, R.A., Fulda, S., Garrido, C., Gougeon, M.L., Green, D.R., Gronemeyer, H., Hajnoczky, G., Hardwick, J.M., Hengartner, M.O., Ichijo, H., Joseph, B., Jost, P.J., Kaufmann, T., Kepp, O., Klionsky, D.J., Knight, R.A., Kumar, S., Lemasters, J.J., Levine, B., Linkermann, A., Lipton, S.A., Lockshin, R.A., Lopez-Otin, C., Lugli, E., Madeo, F., Malorni, W., Marine, J.C., Martin, S.J., Martinou, J.C., Medema, J.P., Meier, P., Melino, S., Mizushima, N., Moll, U., Munoz-Pinedo, C., Nunez, G., Oberst, A., Panaretakis, T., Penninger, J.M., Peter, M.E., Piacentini, M., Pinton, P., Prehn, J.H., Puthalakath, H., Rabinovich, G.A., Ravichandran, K.S., Rizzuto, R., Rodrigues, C.M., Rubinsztein, D.C., Rudel, T., Shi, Y., Simon, H.U., Stockwell, B.R., Szabadkai, G., Tait, S.W., Tang, H.L., Tavernarakis, N., Tsujimoto, Y., Vanden Berghe, T., Vandenabeele, P., Villunger, A., Wagner, E.F., et al. (2015a). Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 22, 58-73. doi: 10.1038/cdd.2014.137.
57. Galluzzi, L., Kepp, O., and Kroemer, G. (2012). Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 13, 780-788. doi: 10.1038/nrm3479.
58. Galluzzi, L., Kepp, O., Vander Heiden, M.G., and Kroemer, G. (2013). Metabolic targets for cancer therapy. Nat Rev Drug Discov 12, 829-846. doi: 10.1038/nrd4145.
59. Galluzzi, L., Pietrocola, F., Bravo-San Pedro, J.M., Amaravadi, R.K., Baehrecke, E.H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D.A., Karantza, V., Kimmelman, A., Kumar, S., Levine, B., Maiuri, M.C., Martin, S.J., Penninger, J., Piacentini, M., Rubinsztein, D.C., Simon, H.U., Simonsen, A., Thorburn, A.M., Velasco, G., Ryan, K.M., and Kroemer, G. (2015c). Autophagy in malignant transformation and cancer progression. EMBO J 34, 856-880. doi: 10.15252/embj.201490784.
60. Galluzzi, L., Senovilla, L., Zitvogel, L., and Kroemer, G. (2012d). The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11, 215-233. doi: 10.1038/nrd3626.
61. Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J.M., Buque, A., Senovilla, L., Baracco, E.E., Bloy, N., Castoldi, F., Abastado, J.P., Agostinis, P., Apte, R.N., Aranda, F., Ayyoub, M., Beckhove, P., Blay, J.Y., Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, V., Clayton, A., Colombo, M.P., Coussens, L., Dhodapkar, M.V., Eggermont, A.M., Fearon, D.T., Fridman, W.H., Fucikova, J., Gabrilovich, D.I., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., Hosmalin, A., Jager, D., Kalinski, P., Karre, K., Kepp, O., Kiessling, R., Kirkwood, J.M., Klein, E., Knuth, A., Lewis, C.E., Liblau, R., Lotze, M.T., Lugli, E., Mach, J.P., Mattei, F., Mavilio, D., Melero, I., Melief, C.J., Mittendorf, E.A., Moretta, L., Odunsi, A., Okada, H., Palucka, A.K., Peter, M.E., Pienta, K.J., Porgador, A., Prendergast, G.C., Rabinovich, G.A., Restifo, N.P., Rizvi, N., Sautes-Fridman, C., Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M.J., Speiser, D.E., Spisek, R., Srivastava, P.K., Talmadge, J.E., Tartour, E., Van Der Burg, S.H., Van Den Eynde, B.J., Vile, R., Wagner, H., Weber, J.S., Whiteside, T.L., Wolchok, J.D., Zitvogel, L., Zou, W., and Kroemer, G. (2014b). Classification of current anticancer immunotherapies. Oncotarget 5, 12472-12508.
62. Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W.H., Galon, J., Sautes-Fridman, C., Tartour, E., Zitvogel, L., and Kroemer, G. (2012g). Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 1, 699-716. doi: 10.4161/onci.20696.
63. Garg, A.D., Dudek, A.M., and Agostinis, P. (2013). Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 39, 355-367. doi: 10.1002/biof.1125.
64. Garg, A.D., Elsen, S., Krysko, D.V., Vandenabeele, P., De Witte, P., and Agostinis, P. (2015). Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget, in press.
65. Garg, A.D., Krysko, D.V., Verfaillie, T., Kaczmarek, A., Ferreira, G.B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A.J., Annaert, W., Golab, J., De Witte, P., Vandenabeele, P., and Agostinis, P. (2012). A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 31, 1062-1079. doi: 10.1038/emboj.2011.497.
66. Garg, A.D., Martin, S., Golab, J., and Agostinis, P. (2014). Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 21, 26-38. doi: 10.1038/cdd.2013.48.
67. Gast, A., Bermejo, J.L., Claus, R., Brandt, A., Weires, M., Weber, A., Plass, C., Sucker, A., Hemminki, K., Schadendorf, D., and Kumar, R. (2011). Association of inherited variation in Tolllike receptor genes with malignant melanoma susceptibility and survival. PLoS One 6, e24370. doi: 10.1371/journal.pone.0024370.
68. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., Perfettini, J.L., Schlemmer, F., Tasdemir, E., Uhl, M., Genin, P., Civas, A., Ryffel, B., Kanellopoulos, J., Tschopp, J., Andre, F., Lidereau, R., Mclaughlin, N.M., Haynes, N.M., Smyth, M.J., Kroemer, G., and Zitvogel, L. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15, 1170-1178. doi: 10.1038/nm.2028.
69. Gold, L.I., Eggleton, P., Sweetwyne, M.T., Van Duyn, L.B., Greives, M.R., Naylor, S.M., Michalak, M., and Murphy-Ullrich, J.E. (2010). Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 24, 665-683. doi: 10.1096/fj.09-145482.
70. Gonzalez-Aguilar, A., Idbaih, A., Boisselier, B., Habbita, N., Rossetto, M., Laurenge, A., Bruno, A., Jouvet, A., Polivka, M., Adam, C., Figarella-Branger, D., Miquel, C., Vital, A., Ghesquieres, H., Gressin, R., Delwail, V., Taillandier, L., Chinot, O., Soubeyran, P., Gyan, E., Choquet, S., Houillier, C., Soussain, C., Tanguy, M.L., Marie, Y., Mokhtari, K., and Hoang-Xuan, K. (2012). Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18, 5203-5211. doi: 10.1158/1078-0432.CCR-12-0845.
71. Guillot, B., Portales, P., Thanh, A.D., Merlet, S., Dereure, O., Clot, J., and Corbeau, P. (2005). The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol 152, 690-696. doi: 10.1111/j.1365-2133.2005.06512.x.
72. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. doi: S0092-8674(00)81683-9 [pii].
73. He, Y., Correa, A.M., Raso, M.G., Hofstetter, W.L., Fang, B., Behrens, C., Roth, J.A., Zhou, Y., Yu, L., Wistuba, Ii, Swisher, S.G., and Pataer, A. (2011). The role of PKR/eIF2alpha signaling pathway in prognosis of non-small cell lung cancer. PLoS One 6, e24855. doi: 10.1371/journal.pone.0024855.
74. Hetz, C. (2012). The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 13, 89-102. doi: 10.1038/nrm3270.
75. Hong, B., Chen, S., Qi, Y., Zhu, J., and Lin, J. (2015). Association of THBS1 rs1478605 T>C in 5'-untranslated regions with the development and progression of gastric cancer. Biomedical Reports 3, 207-214. doi: 10.3892/br.2015.414.
76. Hsu, W.M., Hsieh, F.J., Jeng, Y.M., Kuo, M.L., Chen, C.N., Lai, D.M., Hsieh, L.J., Wang, B.T., Tsao, P.N., Lee, H., Lin, M.T., Lai, H.S., and Chen, W.J. (2005). Calreticulin expression in neuroblastoma-a novel independent prognostic factor. Ann Oncol 16, 314-321. doi: 10.1093/annonc/mdi062.
77. Hsu, W.M., Huang, C.C., Wu, P.Y., Lee, H., Huang, M.C., Tai, M.H., and Chuang, J.H. (2013). Toll-like receptor 3 expression inhibits cell invasion and migration and predicts a favorable prognosis in neuroblastoma. Cancer Lett 336, 338-346. doi: 10.1016/j.canlet.2013.03.024.
78. Ilander, M., Kreutzman, A., Rohon, P., Melo, T., Faber, E., Porkka, K., Vakkila, J., and Mustjoki, S. (2014). Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy. PLoS One 9, e87794. doi: 10.1371/journal.pone.0087794.
79. Janetzki, S., Palla, D., Rosenhauer, V., Lochs, H., Lewis, J.J., and Srivastava, P.K. (2000). Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88, 232-238.
80. Jiang, L., Huang, S., Li, W., Zhang, D., Zhang, S., Zhang, W., Zheng, P., and Chen, Z. (2012). Expression of autophagy and ER stress-related proteins in primary salivary adenoid cystic carcinoma. Pathol Res Pract 208, 635-641. doi: 10.1016/j.prp.2012.07.008.
81. Jonasch, E., Wood, C., Tamboli, P., Pagliaro, L.C., Tu, S.M., Kim, J., Srivastava, P., Perez, C., Isakov, L., and Tannir, N. (2008). Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98, 1336-1341. doi: 10.1038/sj.bjc.6604266.
82. Junjie, X., Songyao, J., Minmin, S., Yanyan, S., Baiyong, S., Xiaxing, D., Jiabin, J., Xi, Z., and Hao, C. (2012). The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer 12, 57. doi: 10.1186/1471-2407-12-57.
83. Kang, R., Zhang, Q., Zeh, H.J., 3rd, Lotze, M.T., and Tang, D. (2013). HMGB1 in cancer: good, bad, or both? Clin Cancer Res 19, 4046-4057. doi: 10.1158/1078-0432.CCR-13-0495.
84. Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A.Q., Menger, L., Zitvogel, L., and Kroemer, G. (2011). Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 30, 61-69. doi: 10.1007/s10555-011-9273-4.
85. Kepp, O., Semeraro, M., Bravo-San Pedro, J.M., Bloy, N., Buque, A., Huang, X., Zhou, H., Senovilla, L., Kroemer, G., and Galluzzi, L. (2015). eIF2alpha phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol. doi: 10.1016/j.semcancer.2015.02.004.
86. Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., Bracci, L., Breckpot, K., Brough, D., Buque, A., Castro, M.G., Cirone, M., Colombo, M.I., Cremer, I., Demaria, S., Dini, L., Eliopoulos, A.G., Faggioni, A., Formenti, S.C., Fucikova, J., Gabriele, L., Gaipl, U.S., Galon, J., Garg, A., Ghiringhelli, F., Giese, N.A., Guo, Z.S., Hemminki, A., Herrmann, M., Hodge, J.W., Holdenrieder, S., Honeychurch, J., Hu, H.M., Huang, X., Illidge, T.M., Kono, K., Korbelik, M., Krysko, D.V., Loi, S., Lowenstein, P.R., Lugli, E., Ma, Y., Madeo, F., Manfredi, A.A., Martins, I., Mavilio, D., Menger, L., Merendino, N., Michaud, M., Mignot, G., Mossman, K.L., Multhoff, G., Oehler, R., Palombo, F., Panaretakis, T., Pol, J., Proietti, E., Ricci, J.E., Riganti, C., Rovere-Querini, P., Rubartelli, A., Sistigu, A., Smyth, M.J., Sonnemann, J., Spisek, R., Stagg, J., Sukkurwala, A.Q., Tartour, E., Thorburn, A., Thorne, S.H., Vandenabeele, P., Velotti, F., Workenhe, S.T., Yang, H., Zong, W.X., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2014). Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691. doi: 10.4161/21624011.2014.955691.
87. Kim, H.J., Bae, J.S., Chang, I.H., Kim, K.D., Lee, J., Shin, H.D., Lee, J.Y., Kim, W.J., Kim, W., and Myung, S.C. (2012a). Sequence variants of Toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol 30, 225-232. doi: 10.1007/s00345-011-0690-3.
88. Kim, K.H., Jo, M.S., Suh, D.S., Yoon, M.S., Shin, D.H., Lee, J.H., and Choi, K.U. (2012d). Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol 10, 193. doi: 10.1186/1477-7819-10-193.
89. Klionsky, D.J., Abdalla, F.C., Abeliovich, H., Abraham, R.T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J.A., Ahn, H.J., Ait-Mohamed, O., Ait-Si-Ali, S., Akematsu, T., Akira, S., Al-Younes, H.M., Al-Zeer, M.A., Albert, M.L., Albin, R.L., Alegre-Abarrategui, J., Aleo, M.F., Alirezaei, M., Almasan, A., Almonte-Becerril, M., Amano, A., Amaravadi, R., Amarnath, S., Amer, A.O., Andrieu-Abadie, N., Anantharam, V., Ann, D.K., Anoopkumar-Dukie, S., Aoki, H., Apostolova, N., Arancia, G., Aris, J.P., Asanuma, K., Asare, N.Y., Ashida, H., Askanas, V., Askew, D.S., Auberger, P., Baba, M., Backues, S.K., Baehrecke, E.H., Bahr, B.A., Bai, X.Y., Bailly, Y., Baiocchi, R., Baldini, G., Balduini, W., Ballabio, A., Bamber, B.A., Bampton, E.T., Banhegyi, G., Bartholomew, C.R., Bassham, D.C., Bast, R.C., Jr., Batoko, H., Bay, B.H., Beau, I., Bechet, D.M., Begley, T.J., Behl, C., Behrends, C., Bekri, S., Bellaire, B., Bendall, L.J., Benetti, L., Berliocchi, L., Bernardi, H., Bernassola, F., Besteiro, S., Bhatia-Kissova, I., Bi, X., Biard-Piechaczyk, M., Blum, J.S., Boise, L.H., Bonaldo, P., Boone, D.L., Bornhauser, B.C., Bortoluci, K.R., Bossis, I., Bost, F., Bourquin, J.P., Boya, P., Boyer-Guittaut, M., Bozhkov, P.V., Brady, N.R., Brancolini, C., Brech, A., Brenman, J.E., Brennand, A., Bresnick, E.H., Brest, P., Bridges, D., Bristol, M.L., Brookes, P.S., Brown, E.J., Brumell, J.H., et al. (2012). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8, 445-544.
90. Ko, A., Kanehisa, A., Martins, I., Senovilla, L., Chargari, C., Dugue, D., Marino, G., Kepp, O., Michaud, M., Perfettini, J.L., Kroemer, G., and Deutsch, E. (2014). Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ 21, 92-99. doi: 10.1038/cdd.2013.124.
91. Ko, Y.H., Cho, Y.S., Won, H.S., Jeon, E.K., An, H.J., Hong, S.U., Park, J.H., and Lee, M.A. (2013). Prognostic significance of autophagy-related protein expression in resected pancreatic ductal adenocarcinoma. Pancreas 42, 829-835. doi: 10.1097/MPA.0b013e318279d0dc.
92. Kohles, N., Nagel, D., Jungst, D., Stieber, P., and Holdenrieder, S. (2012). Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol 33, 2401-2409. doi: 10.1007/s13277-012-0504-2.
93. Korbelik, M., Sun, J., and Cecic, I. (2005). Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 65, 1018-1026.
94. Kroemer, G., Galluzzi, L., Kepp, O., and Zitvogel, L. (2013). Immunogenic cell death in cancer therapy. Annu Rev Immunol 31, 51-72. doi: 10.1146/annurev-immunol-032712-100008.
95. Krysko, D.V., Agostinis, P., Krysko, O., Garg, A.D., Bachert, C., Lambrecht, B.N., and Vandenabeele, P. (2011). Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 32, 157-164. doi: 10.1016/j.it.2011.01.005.
96. Krysko, D.V., Garg, A.D., Kaczmarek, A., Krysko, O., Agostinis, P., and Vandenabeele, P. (2012). Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12, 860-875. doi: 10.1038/nrc3380.
97. Kung, C.T., Hsiao, S.Y., Tsai, T.C., Su, C.M., Chang, W.N., Huang, C.R., Wang, H.C., Lin, W.C., Chang, H.W., Lin, Y.J., Cheng, B.C., Su, B.Y., Tsai, N.W., and Lu, C.H. (2012). Plasma nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients in the emergency room. J Transl Med 10, 130. doi: 10.1186/1479-5876-10-130.
98. Kunzli, B.M., Berberat, P.O., Giese, T., Csizmadia, E., Kaczmarek, E., Baker, C., Halaceli, I., Buchler, M.W., Friess, H., and Robson, S.C. (2007). Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol 292, G223-230. doi: 10.1152/ajpgi.00259.2006.
99. Ladoire, S., Chaba, K., Martins, I., Sukkurwala, A.Q., Adjemian, S., Michaud, M., Poirier-Colame, V., Andreiuolo, F., Galluzzi, L., White, E., Rosenfeldt, M., Ryan, K.M., Zitvogel, L., and Kroemer, G. (2012). Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy 8, 1175-1184. doi: 10.4161/auto.20353.
100. Lee, H., Song, M., Shin, N., Shin, C.H., Min, B.S., Kim, H.S., Yoo, J.S., and Kim, H. (2012). Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 7, e34318. doi: 10.1371/journal.pone.0034318.
101. Lee, Y.J., Hah, Y.J., Kang, Y.N., Kang, K.J., Hwang, J.S., Chung, W.J., Cho, K.B., Park, K.S., Kim, E.S., Seo, H.Y., Kim, M.K., Park, K.G., and Jang, B.K. (2013). The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PLoS One 8, e81540. doi: 10.1371/journal.pone.0081540.
102. Li, G., and Zheng, Z. (2013). Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumour Biol 34, 1589-1594. doi: 10.1007/s13277-013-0689-z.
103. Liikanen, I., Ahtiainen, L., Hirvinen, M.L., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S., Koski, A., Kangasniemi, L., Pesonen, S.K., Oksanen, M., Laasonen, L., Partanen, K., Joensuu, T., Zhao, F., Kanerva, A., and Hemminki, A. (2013). Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 21, 1212-1223. doi: 10.1038/mt.2013.51.
104. Liikanen, I., Koski, A., Merisalo-Soikkeli, M., Hemminki, O., Oksanen, M., Kairemo, K., Joensuu, T., Kanerva, A., and Hemminki, A. (2015). Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology 4, e989771. doi: 10.4161/2162402X.2014.989771.
105. Liu, A., Fang, H., Dirsch, O., Jin, H., and Dahmen, U. (2012a). Oxidation of HMGB1 causes attenuation of its pro-inflammatory activity and occurs during liver ischemia and reperfusion. PLoS One 7, e35379. doi: 10.1371/journal.pone.0035379.
106. Liu, F., Zhang, Y., Peng, Z., Gao, H., Xu, L., and Chen, M. (2012b). High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med 10, 135. doi: 10.1186/1479-5876-10-135.
107. Liu, R., Gong, J., Chen, J., Li, Q., Song, C., Zhang, J., Li, Y., Liu, Z., Dong, Y., Chen, L., and Jin, B. (2012d). Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother 61, 855-864. doi: 10.1007/s00262-011-1146-8.
108. Liu, Y., Xie, C., Zhang, X., Huang, D., Zhou, X., Tan, P., Qi, L., Hu, G., Tian, Y., and Qiu, Y. (2010). Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46, 3007-3015. doi: 10.1016/j.ejca.2010.07.016.
109. Lu, S., Pardini, B., Cheng, B., Naccarati, A., Huhn, S., Vymetalkova, V., Vodickova, L., Buchler, T., Hemminki, K., Vodicka, P., and Forsti, A. (2014). Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival. PLoS One 9, e111061. doi: 10.1371/journal.pone.0111061.
110. Ma, Y., Adjemian, S., Mattarollo, S.R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J.P., Hannani, D., Duret, H., Steegh, K., Martins, I., Schlemmer, F., Michaud, M., Kepp, O., Sukkurwala, A.Q., Menger, L., Vacchelli, E., Droin, N., Galluzzi, L., Krzysiek, R., Gordon, S., Taylor, P.R., Van Endert, P., Solary, E., Smyth, M.J., Zitvogel, L., and Kroemer, G. (2013a). Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigenpresenting cells. Immunity 38, 729-741. doi: 10.1016/j.immuni.2013.03.003.
111. Ma, Y., Adjemian, S., Yang, H., Catani, J.P., Hannani, D., Martins, I., Michaud, M., Kepp, O., Sukkurwala, A.Q., Vacchelli, E., Galluzzi, L., Zitvogel, L., and Kroemer, G. (2013b). ATPdependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2, e24568. doi: 10.4161/onci.24568.
112. Ma, Y., Galluzzi, L., Zitvogel, L., and Kroemer, G. (2013c). Autophagy and cellular immune responses. Immunity 39, 211-227. doi: 10.1016/j.immuni.2013.07.017.
113. Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D., Jr., Van Rooijen, N., and Weissman, I.L. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299. doi: 10.1016/j.cell.2009.05.045.
114. Maki, R.G., Livingston, P.O., Lewis, J.J., Janetzki, S., Klimstra, D., Desantis, D., Srivastava, P.K., and Brennan, M.F. (2007). A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 52, 1964-1972. doi: 10.1007/s10620-006-9205-2.
115. Mandal, R.K., George, G.P., and Mittal, R.D. (2012). Association of Toll-like receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population. Mol Biol Rep 39, 7263-7269. doi: 10.1007/s11033-012-1556-5.
116. Martins, I., Kepp, O., Menger, L., Michaud, M., Adjemian, S., Sukkurwala, A.Q., Vacchelli, E., Galluzzi, L., and Kroemer, G. (2013). Fluorescent biosensors for the detection of HMGB1 release. Methods Mol Biol 1004, 43-56. doi: 10.1007/978-1-62703-383-1_4.
117. Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Seror, C., Metivier, D., Perfettini, J.L., Zitvogel, L., and Kroemer, G. (2009). Chemotherapy induces ATP release from tumor cells. Cell Cycle 8, 3723-3728.
118. Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A.Q., Shen, S., Kepp, O., Metivier, D., Galluzzi, L., Perfettini, J.L., Zitvogel, L., and Kroemer, G. (2014). Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 21, 79-91. doi: 10.1038/cdd.2013.75.
119. Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 12, 991-1045. doi: 10.1146/annurev.iy.12.040194.005015.
120. Mazzaferro, V., Coppa, J., Carrabba, M.G., Rivoltini, L., Schiavo, M., Regalia, E., Mariani, L., Camerini, T., Marchiano, A., Andreola, S., Camerini, R., Corsi, M., Lewis, J.J., Srivastava, P.K., and Parmiani, G. (2003). Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9, 3235-3245.
121. Mcdonald, B., Pittman, K., Menezes, G.B., Hirota, S.A., Slaba, I., Waterhouse, C.C., Beck, P.L., Muruve, D.A., and Kubes, P. (2010). Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330, 362-366. doi: 10.1126/science.1195491.
122. Meacham, C.E., and Morrison, S.J. (2013). Tumour heterogeneity and cancer cell plasticity. Nature 501, 328-337. doi: 10.1038/nature12624.
123. Michaud, M., Martins, I., Sukkurwala, A.Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., Rello-Varona, S., Tailler, M., Menger, L., Vacchelli, E., Galluzzi, L., Ghiringhelli, F., Di Virgilio, F., Zitvogel, L., and Kroemer, G. (2011). Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573-1577. doi: 10.1126/science.1208347.
124. Michaud, M., Sukkurwala, A.Q., Martins, I., Shen, S., Zitvogel, L., and Kroemer, G. (2012). Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology 1, 393-395. doi: 10.4161/onci.19070.
125. Mittal, D., Gubin, M.M., Schreiber, R.D., and Smyth, M.J. (2014). New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 27, 16-25. doi: 10.1016/j.coi.2014.01.004.
126. Mozos, A., Roue, G., Lopez-Guillermo, A., Jares, P., Campo, E., Colomer, D., and Martinez, A. (2011). The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. Am J Pathol 179, 2601-2610. doi: 10.1016/j.ajpath.2011.07.031.
127. Multhoff, G., Botzler, C., Jennen, L., Schmidt, J., Ellwart, J., and Issels, R. (1997). Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol 158, 4341-4350.
128. Multhoff, G., Botzler, C., Wiesnet, M., Eissner, G., and Issels, R. (1995). CD3-large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood 86, 1374-1382.
129. Nevadunsky, N.S., Korneeva, I., Caputo, T., and Witkin, S.S. (2012). Mannose-binding lectin codon 54 genetic polymorphism and vaginal protein levels in women with gynecologic malignancies. Eur J Obstet Gynecol Reprod Biol 163, 216-218. doi: 10.1016/j.ejogrb.2012.04.020.
130. Nieters, A., Beckmann, L., Deeg, E., and Becker, N. (2006). Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 7, 615-624. doi: 10.1038/sj.gene.6364337.
131. Novikov, A., Cardone, M., Thompson, R., Shenderov, K., Kirschman, K.D., Mayer-Barber, K.D., Myers, T.G., Rabin, R.L., Trinchieri, G., Sher, A., and Feng, C.G. (2011). Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. J Immunol 187, 2540-2547. doi: 10.4049/jimmunol.1100926.
132. Nuckel, H., Frey, U.H., Durig, J., Duhrsen, U., and Siffert, W. (2004). 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome. Eur J Haematol 72, 259-263. doi: 10.1111/j.0902-4441.2003.00210.x.
133. Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J.L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., Metivier, D., Larochette, N., Van Endert, P., Ciccosanti, F., Piacentini, M., Zitvogel, L., and Kroemer, G. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13, 54-61. doi: 10.1038/nm1523.
134. Oka, T., Hikoso, S., Yamaguchi, O., Taneike, M., Takeda, T., Tamai, T., Oyabu, J., Murakawa, T., Nakayama, H., Nishida, K., Akira, S., Yamamoto, A., Komuro, I., and Otsu, K. (2012). Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485, 251-255. doi: 10.1038/nature10992.
135. Oki, Y., Mclaughlin, P., Fayad, L.E., Pro, B., Mansfield, P.F., Clayman, G.L., Medeiros, L.J., Kwak, L.W., Srivastava, P.K., and Younes, A. (2007). Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109, 77-83. doi: 10.1002/cncr.22389.
136. Pan, H., He, L., Wang, B., and Niu, W. (2014). The relationship between RAGE gene four common polymorphisms and breast cancer risk in northeastern Han Chinese. Sci Rep 4, 4355. doi: 10.1038/srep04355.
137. Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A.C., Chapman, D.C., Durchschlag, M., Joza, N., Pierron, G., Van Endert, P., Yuan, J., Zitvogel, L., Madeo, F., Williams, D.B., and Kroemer, G. (2009). Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28, 578-590. doi: 10.1038/emboj.2009.1.
138. Paneesha, S., Starczynski, J., Pepper, C., Delgado, J., Hooper, L., Fegan, C., and Pratt, G. (2006). The P2X7 receptor gene polymorphism 1513 A->C has no effect on clinical prognostic markers and survival in multiple myeloma. Leuk Lymphoma 47, 281-284. doi: 10.1080/10428190500305901.
139. Papewalis, C., Jacobs, B., Wuttke, M., Ullrich, E., Baehring, T., Fenk, R., Willenberg, H.S., Schinner, S., Cohnen, M., Seissler, J., Zacharowski, K., Scherbaum, W.A., and Schott, M. (2008). IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol 180, 1462-1470.
140. Peng, R.Q., Chen, Y.B., Ding, Y., Zhang, R., Zhang, X., Yu, X.J., Zhou, Z.W., Zeng, Y.X., and Zhang, X.S. (2010a). Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol 16, 2428-2434.
141. Peng, R.Q., Wu, X.J., Ding, Y., Li, C.Y., Yu, X.J., Zhang, X., Pan, Z.Z., Wan, D.S., Zheng, L.M., Zeng, Y.X., and Zhang, X.S. (2010c). Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer 10, 496. doi: 10.1186/1471-2407-10-496.
142. Perry, C., Hazan-Halevy, I., Kay, S., Cipok, M., Grisaru, D., Deutsch, V., Polliack, A., Naparstek, E., and Herishanu, Y. (2012). Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia. Ann Hematol 91, 1271-1279. doi: 10.1007/s00277-012-1425-2.
143. Pilla, L., Patuzzo, R., Rivoltini, L., Maio, M., Pennacchioli, E., Lamaj, E., Maurichi, A., Massarut, S., Marchiano, A., Santantonio, C., Tosi, D., Arienti, F., Cova, A., Sovena, G., Piris, A., Nonaka, D., Bersani, I., Di Florio, A., Luigi, M., Srivastava, P.K., Hoos, A., Santinami, M., and Parmiani, G. (2006). A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 55, 958-968. doi: 10.1007/s00262-005-0084-8.
144. Pulte, D., Furman, R.R., Broekman, M.J., Drosopoulos, J.H., Ballard, H.S., Olson, K.E., Kizer, J.R., and Marcus, A.J. (2011). CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11, 367-372. doi: 10.1016/j.clml.2011.06.005.
145. Qiu, G., Li, Y., Liu, Z., Wang, M., Ge, J., and Bai, X. (2014). Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol 31, 316. doi: 10.1007/s12032-014-0316-x.
146. Rabiet, M.J., Huet, E., and Boulay, F. (2005). Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol 35, 2486-2495. doi: 10.1002/eji.200526338.
147. Raoof, M., Zhang, Q., Itagaki, K., and Hauser, C.J. (2010). Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. J Trauma 68, 1328-1332; discussion 1332-1324. doi: 10.1097/TA.0b013e3181dcd28d.
148. Rovere-Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catalanotti, F., Giazzon, M., Dumitriu, I.E., Muller, S., Iannacone, M., Traversari, C., Bianchi, M.E., and Manfredi, A.A. (2004). HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5, 825-830. doi: 10.1038/sj.embor.7400205.
149. Salaun, B., Zitvogel, L., Asselin-Paturel, C., Morel, Y., Chemin, K., Dubois, C., Massacrier, C., Conforti, R., Chenard, M.P., Sabourin, J.C., Goubar, A., Lebecque, S., Pierres, M., Rimoldi, D., Romero, P., and Andre, F. (2011). TLR3 as a biomarker for the therapeutic efficacy of doublestranded RNA in breast cancer. Cancer Res 71, 1607-1614. doi: 10.1158/0008-5472.CAN-10-3490.
150. Sautes-Fridman, C., Cherfils-Vicini, J., Damotte, D., Fisson, S., Fridman, W.H., Cremer, I., and Dieu-Nosjean, M.C. (2011). Tumor microenvironment is multifaceted. Cancer Metastasis Rev 30, 13-25. doi: 10.1007/s10555-011-9279-y.
151. Scaffidi, P., Misteli, T., and Bianchi, M.E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195. doi: 10.1038/nature00858.
152. Schardt, J.A., Mueller, B.U., and Pabst, T. (2011). Activation of the unfolded protein response in human acute myeloid leukemia. Methods Enzymol 489, 227-243. doi: 10.1016/B978-0-12-385116-1.00013-3.
153. Schardt, J.A., Weber, D., Eyholzer, M., Mueller, B.U., and Pabst, T. (2009). Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clin Cancer Res 15, 3834-3841. doi: 10.1158/1078-0432.CCR-08-2870.
154. Schiraldi, M., Raucci, A., Munoz, L.M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., Thelen, M., Varani, L., Mellado, M., Proudfoot, A., Bianchi, M.E., and Uguccioni, M. (2012). HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209, 551-563. doi: 10.1084/jem.20111739.
155. Schreiber, R.D., Old, L.J., and Smyth, M.J. (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570. doi: 10.1126/science.1203486.
156. Segawa, K., Kurata, S., Yanagihashi, Y., Brummelkamp, T.R., Matsuda, F., and Nagata, S. (2014). Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science 344, 1164-1168. doi: 10.1126/science.1252809.
157. Senovilla, L., Aranda, F., Galluzzi, L., and Kroemer, G. (2014). Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 30, 24-31. doi: 10.1016/j.coi.2014.05.009.
158. Senovilla, L., Galluzzi, L., Zitvogel, L., and Kroemer, G. (2013). Immunosurveillance as a regulator of tissue homeostasis. Trends Immunol 34, 471-481. doi: 10.1016/j.it.2013.06.005.
159. Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W.H., Sautes-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2012a). Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1, 1323-1343. doi: 10.4161/onci.22009.
160. Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., Shen, S., Marino, G., Criollo, A., Boileve, A., Job, B., Ladoire, S., Ghiringhelli, F., Sistigu, A., Yamazaki, T., Rello-Varona, S., Locher, C., Poirier-Colame, V., Talbot, M., Valent, A., Berardinelli, F., Antoccia, A., Ciccosanti, F., Fimia, G.M., Piacentini, M., Fueyo, A., Messina, N.L., Li, M., Chan, C.J., Sigl, V., Pourcher, G., Ruckenstuhl, C., Carmona-Gutierrez, D., Lazar, V., Penninger, J.M., Madeo, F., Lopez-Otin, C., Smyth, M.J., Zitvogel, L., Castedo, M., and Kroemer, G. (2012b). An immunosurveillance mechanism controls cancer cell ploidy. Science 337, 1678-1684. doi: 10.1126/science.1224922.
161. Shiratsuchi, A., Watanabe, I., Takeuchi, O., Akira, S., and Nakanishi, Y. (2004). Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J Immunol 172, 2039-2047.
162. Sims, G.P., Rowe, D.C., Rietdijk, S.T., Herbst, R., and Coyle, A.J. (2010). HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28, 367-388. doi: 10.1146/annurev.immunol.021908.132603.
163. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remedios, C., Fend, L., Hannani, D., Aymeric, L., Ma, Y., Niso-Santano, M., Kepp, O., Schultze, J.L., Tuting, T., Belardelli, F., Bracci, L., La Sorsa, V., Ziccheddu, G., Sestili, P., Urbani, F., Delorenzi, M., Lacroix-Triki, M., Quidville, V., Conforti, R., Spano, J.P., Pusztai, L., Poirier-Colame, V., Delaloge, S., Penault-Llorca, F., Ladoire, S., Arnould, L., Cyrta, J., Dessoliers, M.C., Eggermont, A., Bianchi, M.E., Pittet, M., Engblom, C., Pfirschke, C., Preville, X., Uze, G., Schreiber, R.D., Chow, M.T., Smyth, M.J., Proietti, E., Andre, F., Kroemer, G., and Zitvogel, L. (2014). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20, 1301-1309. doi: 10.1038/nm.3708.
164. Slattery, M.L., Herrick, J.S., Bondurant, K.L., and Wolff, R.K. (2012). Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer 130, 2974-2980. doi: 10.1002/ijc.26314.
165. Song, J., Kim, D.Y., Kim, C.S., Kim, H.J., Lee, D.H., Lee, H.M., Ko, W., and Lee, G. (2009). The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet 190, 88-92. doi: 10.1016/j.cancergencyto.2008.12.011.
166. Spisek, R., Charalambous, A., Mazumder, A., Vesole, D.H., Jagannath, S., and Dhodapkar, M.V. (2007). Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109, 4839-4845. doi: 10.1182/blood-2006-10-054221.
167. Spisek, R., and Dhodapkar, M.V. (2007). Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 6, 1962-1965.
168. Starczynski, J., Pepper, C., Pratt, G., Hooper, L., Thomas, A., Hoy, T., Milligan, D., Bentley, P., and Fegan, C. (2003). The P2X7 receptor gene polymorphism 1513 A->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. Br J Haematol 123, 66-71.
169. Stebbing, J., Bower, M., Gazzard, B., Wildfire, A., Pandha, H., Dalgleish, A., and Spicer, J. (2004). The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressors. Clin Exp Immunol 138, 312-316. doi: 10.1111/j.1365-2249.2004.02619.x.
170. Suzuki, S., Yokobori, T., Tanaka, N., Sakai, M., Sano, A., Inose, T., Sohda, M., Nakajima, M., Miyazaki, T., Kato, H., and Kuwano, H. (2012a). CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 28, 465-472. doi: 10.3892/or.2012.1831.
171. Suzuki, Y., Mimura, K., Yoshimoto, Y., Watanabe, M., Ohkubo, Y., Izawa, S., Murata, K., Fujii, H., Nakano, T., and Kono, K. (2012c). Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72, 3967-3976. doi: 10.1158/0008-5472.CAN-12-0851.
172. Tabata, C., Shibata, E., Tabata, R., Kanemura, S., Mikami, K., Nogi, Y., Masachika, E., Nishizaki, T., and Nakano, T. (2013). Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 13, 205. doi: 10.1186/1471-2407-13-205.
173. Tahara, T., Arisawa, T., Wang, F., Shibata, T., Nakamura, M., Sakata, M., Hirata, I., and Nakano, H. (2007). Toll-like receptor 2-196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 98, 1790-1794. doi: 10.1111/j.1349-7006.2007.00590.x.
174. Tang, H., Sebti, S., Titone, R., Zhou, Y., Isidoro, C., Ross, T.S., Hibshoosh, H., Xiao, G., Packer, M., Xie, Y., and Levine, B. (2015). Decreased mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. EBioMedicine 2, 255-263. doi: 10.1016/j.ebiom.2015.01.008.
175. Tesarova, P., Kalousova, M., Jachymova, M., Mestek, O., Petruzelka, L., and Zima, T. (2007). Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 25, 720-725. doi: 10.1080/07357900701560521.
176. Testori, A., Richards, J., Whitman, E., Mann, G.B., Lutzky, J., Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J.M., Hoos, A., Yuh, L., Gupta, R., Srivastava, P.K., and Group, C.S. (2008). Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 26, 955-962. doi: 10.1200/JCO.2007.11.9941.
177. Theodoropoulos, G.E., Gazouli, M., Vaiopoulou, A., Leandrou, M., Nikouli, S., Vassou, E., Kouraklis, G., and Nikiteas, N. (2011). Polymorphisms of caspase 8 and caspase 9 gene and colorectal cancer susceptibility and prognosis. Int J Colorectal Dis 26, 1113-1118. doi: 10.1007/s00384-011-1217-5.
178. Thunberg, U., Tobin, G., Johnson, A., Soderberg, O., Padyukov, L., Hultdin, M., Klareskog, L., Enblad, G., Sundstrom, C., Roos, G., and Rosenquist, R. (2002). Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet 360, 1935-1939. doi: 10.1016/S0140-6736(02)11917-9.
179. Tian, J., Avalos, A.M., Mao, S.Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., Hua, J., An, L.L., Audoly, L., La Rosa, G., Bierhaus, A., Naworth, P., Marshak-Rothstein, A., Crow, M.K., Fitzgerald, K.A., Latz, E., Kiener, P.A., and Coyle, A.J. (2007). Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8, 487-496. doi: 10.1038/ni1457.
180. Tittarelli, A., Gonzalez, F.E., Pereda, C., Mora, G., Munoz, L., Saffie, C., Garcia, T., Diaz, D., Falcon, C., Hermoso, M., Lopez, M.N., and Salazar-Onfray, F. (2012). Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother 61, 2067-2077. doi: 10.1007/s00262-012-1268-7.
181. Tufi, R., Panaretakis, T., Bianchi, K., Criollo, A., Fazi, B., Di Sano, F., Tesniere, A., Kepp, O., Paterlini-Brechot, P., Zitvogel, L., Piacentini, M., Szabadkai, G., and Kroemer, G. (2008). Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ 15, 274-282. doi: 10.1038/sj.cdd.4402275.
182. Uramoto, H., Sugio, K., Oyama, T., Nakata, S., Ono, K., Yoshimastu, T., Morita, M., and Yasumoto, K. (2005). Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49, 55-62. doi: 10.1016/j.lungcan.2004.12.011.
183. Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautes-Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2014a). Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 3, e27878. doi: 10.4161/onci.27878.
184. Vacchelli, E., Aranda, F., Obrist, F., Eggermont, A., Galon, J., Cremer, I., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2014b). Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 3, e29030. doi: 10.4161/onci.29030.
185. Vacchelli, E., Eggermont, A., Fridman, W.H., Galon, J., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2013a). Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2, e24850. doi: 10.4161/onci.24850.
186. Vacchelli, E., Martins, I., Eggermont, A., Fridman, W.H., Galon, J., Sautes-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2012). Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 1, 1557-1576. doi: 10.4161/onci.22428.
187. Vacchelli, E., Prada, N., Kepp, O., and Galluzzi, L. (2013b). Current trends of anticancer immunochemotherapy. Oncoimmunology 2, e25396. doi: 10.4161/onci.25396.
188. Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W.H., Galon, J., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2013d). Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2, e23510. doi: 10.4161/onci.23510.
189. Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D.J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., Shams, S.S., Yang, H., Varani, L., Andersson, U., Tracey, K.J., Bachi, A., Uguccioni, M., and Bianchi, M.E. (2012). Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209, 1519-1528. doi: 10.1084/jem.20120189.
190. Wang, D., Li, T., Ye, G., Shen, Z., Hu, Y., Mou, T., Yu, J., Li, S., Liu, H., and Li, G. (2015a). Overexpression of the Receptor for Advanced Glycation Endproducts (RAGE) is associated with poor prognosis in gastric cancer. PLoS One 10, e0122697. doi: 10.1371/journal.pone.0122697.
191. Wang, E.L., Qian, Z.R., Nakasono, M., Tanahashi, T., Yoshimoto, K., Bando, Y., Kudo, E., Shimada, M., and Sano, T. (2010). High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 102, 908-915. doi: 10.1038/sj.bjc.6605558.
192. Wang, H., Tan, M., Zhang, S., Li, X., Gao, J., Zhang, D., Hao, Y., Gao, S., Liu, J., and Lin, B. (2015c). Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol Sci 16, 3391-3404. doi: 10.3390/ijms16023391.
193. Wang, M.H., Helzlsouer, K.J., Smith, M.W., Hoffman-Bolton, J.A., Clipp, S.L., Grinberg, V., De Marzo, A.M., Isaacs, W.B., Drake, C.G., Shugart, Y.Y., and Platz, E.A. (2009). Association of IL10 and other immune response-and obesity-related genes with prostate cancer in CLUE II. Prostate 69, 874-885. doi: 10.1002/pros.20933.
194. Wang, X., Cui, E., Zeng, H., Hua, F., Wang, B., Mao, W., and Feng, X. (2012). RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS One 7, e43734. doi: 10.1371/journal.pone.0043734.
195. Wemeau, M., Kepp, O., Tesniere, A., Panaretakis, T., Flament, C., De Botton, S., Zitvogel, L., Kroemer, G., and Chaput, N. (2010). Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 1, e104. doi: 10.1038/cddis.2010.82.
196. West, A.P., Khoury-Hanold, W., Staron, M., Tal, M.C., Pineda, C.M., Lang, S.M., Bestwick, M., Duguay, B.A., Raimundo, N., Macduff, D.A., Kaech, S.M., Smiley, J.R., Means, R.E., Iwasaki, A., and Shadel, G.S. (2015). Mitochondrial DNA stress primes the antiviral innate immune response. Nature 520, 553-557. doi: 10.1038/nature14156.
197. Whiteside, T.L. (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912. doi: 10.1038/onc.2008.271.
198. Wiley, J.S., Dao-Ung, L.P., Gu, B.J., Sluyter, R., Shemon, A.N., Li, C., Taper, J., Gallo, J., and Manoharan, A. (2002). A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet 359, 1114-1119. doi: 10.1016/S0140-6736(02)08156-4.
199. Wittwer, C., Boeck, S., Heinemann, V., Haas, M., Stieber, P., Nagel, D., and Holdenrieder, S. (2013). Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer 133, 2619-2630. doi: 10.1002/ijc.28294.
200. Wood, C., Srivastava, P., Bukowski, R., Lacombe, L., Gorelov, A.I., Gorelov, S., Mulders, P., Zielinski, H., Hoos, A., Teofilovici, F., Isakov, L., Flanigan, R., Figlin, R., Gupta, R., Escudier, B., and Group, C.R.S. (2008). An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372, 145-154. doi: 10.1016/S0140-6736(08)60697-2.
201. Wood, C.G., and Mulders, P. (2009). Vitespen: a preclinical and clinical review. Future Oncol 5, 763-774. doi: 10.2217/fon.09.46.
202. Wu, D., Ding, Y., Wang, S., Zhang, Q., and Liu, L. (2008). Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 216, 167-175. doi: 10.1002/path.2391.
203. Xiao, J., Ding, Y., Huang, J., Li, Q., Liu, Y., Ni, W., Zhang, Y., Zhu, Y., Chen, L., and Chen, B. (2014). The association of HMGB1 gene with the prognosis of HCC. PLoS One 9, e89097. doi: 10.1371/journal.pone.0089097.
204. Xu, H.C., Grusdat, M., Pandyra, A.A., Polz, R., Huang, J., Sharma, P., Deenen, R., Kohrer, K., Rahbar, R., Diefenbach, A., Gibbert, K., Lohning, M., Hocker, L., Waibler, Z., Haussinger, D., Mak, T.W., Ohashi, P.S., Lang, K.S., and Lang, P.A. (2014). Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 40, 949-960. doi: 10.1016/j.immuni.2014.05.004.
205. Xu, H.L., Xu, W.H., Cai, Q., Feng, M., Long, J., Zheng, W., Xiang, Y.B., and Shu, X.O. (2009). Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: a population-based, case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev 18, 2114-2122. doi: 10.1158/1055-9965.EPI-09-0152.
206. Xu, S., Shao, Q.Q., Sun, J.T., Yang, N., Xie, Q., Wang, D.H., Huang, Q.B., Huang, B., Wang, X.Y., Li, X.G., and Qu, X. (2013). Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol 15, 1160-1172. doi: 10.1093/neuonc/not067.
207. Yamazaki, T., Hannani, D., Poirier-Colame, V., Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J.P., Freudenberg, M., Galanos, C., Andre, F., Kroemer, G., and Zitvogel, L. (2014). Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 21, 69-78. doi: 10.1038/cdd.2013.72.
208. Yang, G.L., Zhang, L.H., Bo, J.J., Huo, X.J., Chen, H.G., Cao, M., Liu, D.M., and Huang, Y.R. (2012). Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 106, 57-61. doi: 10.1002/jso.23040.
209. Yao, X., Zhao, G., Yang, H., Hong, X., Bie, L., and Liu, G. (2010). Overexpression of highmobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 136, 677-684. doi: 10.1007/s00432-009-0706-1.
210. Yeyeodu, S.T., Kidd, L.R., Oprea-Ilies, G.M., Burns, B.G., Vancleave, T.T., Shim, J.Y., and Kimbro, K.S. (2013). IRAK4 and TLR3 Sequence Variants may Alter Breast Cancer Risk among African-American Women. Front Immunol 4, 338. doi: 10.3389/fimmu.2013.00338.
211. Yu, Y., Tang, D., and Kang, R. (2015). Oxidative stress-mediated HMGB1 biology. Front Physiol 6, 93. doi: 10.3389/fphys.2015.00093.
212. Yuan, M.M., Xu, Y.Y., Chen, L., Li, X.Y., Qin, J., and Shen, Y. (2015). TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. BMC Cancer 15, 245. doi: 10.1186/s12885-015-1262-5.
213. Zappasodi, R., Pupa, S.M., Ghedini, G.C., Bongarzone, I., Magni, M., Cabras, A.D., Colombo, M.P., Carlo-Stella, C., Gianni, A.M., and Di Nicola, M. (2010). Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 70, 9062-9072. doi: 10.1158/0008-5472.CAN-10-1825.
214. Zeljic, K., Supic, G., Jovic, N., Kozomara, R., Brankovic-Magic, M., Obrenovic, M., and Magic, Z. (2014). Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis 20, 416-424. doi: 10.1111/odi.12144.
215. Zeng, G., Aldridge, M.E., Tian, X., Seiler, D., Zhang, X., Jin, Y., Rao, J., Li, W., Chen, D., Langford, M.P., Duggan, C., Belldegrun, A.S., and Dubinett, S.M. (2006). Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 177, 3582-3589.
216. Zhang, L.Y., Ibbotson, R.E., Orchard, J.A., Gardiner, A.C., Seear, R.V., Chase, A.J., Oscier, D.G., and Cross, N.C. (2003). P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia 17, 2097-2100. doi: 10.1038/sj.leu.2403125.
217. Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., and Hauser, C.J. (2010). Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107. doi: 10.1038/nature08780.
218. Zhang, S., Hou, X., Zi, S., Wang, Y., Chen, L., and Kong, B. (2013). Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients. Cell Physiol Biochem 31, 525-531. doi: 10.1159/000350073.
219. Zhao, C.B., Bao, J.M., Lu, Y.J., Zhao, T., Zhou, X.H., Zheng, D.Y., and Zhao, S.C. (2014). Coexpression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res 4, 369-377.
220. Zhu, Y., Huang, J.M., Zhang, G.N., Zha, X., and Deng, B.F. (2012). Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med 10, 77. doi: 10.1186/1479-5876-10-77.
221. Zidi, S., Verdi, H., Yilmaz-Yalcin, Y., Yazici, A.C., Gazouani, E., Mezlini, A., Atac, F.B., and Yacoubi-Loueslati, B. (2014). Impact of Toll-Like Receptors 2/3/4/9, IL-1-alpha/beta and TNFalpha Polymorphisms in Cervical Cancer Susceptibility in Tunisia: Genetic polymorphisms implicated in the occurence of Cervical Cancer. Pathol Oncol Res. doi: 10.1007/s12253-014-9793-7.
222. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., and Kroemer, G. (2015). Type I interferons in anticancer immunity. Nat Rev Immunol. doi: 10.1038/nri3845.
223. Zitvogel, L., Galluzzi, L., Smyth, M.J., and Kroemer, G. (2013). Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74-88. doi: 10.1016/j.immuni.2013.06.014.
224. Zitvogel, L., Kepp, O., Galluzzi, L., and Kroemer, G. (2012). Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13, 343-351. doi: 10.1038/ni.2224.
225. Zitvogel, L., Tesniere, A., and Kroemer, G. (2006). Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6, 715-727. doi: 10.1038/nri1936.